RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...
The Daily Caller on MSN
Ex-FDA commissioners against higher vaccine standards took $6 million from COVID vaccine makers
Ten of the twelve former Food and Drug Administration (FDA) commissioners and acting commissioners opposed to the Trump ...
Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.
PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587), announced the achievement of a preclinical development milestone in ...
Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...
With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Alnylam is making a $250 million investment in its Massachusetts manufacturing facility. The investment comes as the company begins to expand beyond rare disease treatments into more common conditions ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback